Quest Diagnostics (DGX) shares reached a new 52-week high after the diagnostic services provider surpassed Q4 2025 financial forecasts and provided a 2026 outlook that exceeded consensus expectations. The company also announced a dividend hike.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Quest Diagnostics hits 52-week high on outlook (DGX:NYSE)
Quest Diagnostics (DGX) shares reached a new 52-week high after the diagnostic services provider surpassed Q4 2025 financial forecasts and provided a 2026 outlook that exceeded consensus expectations. The company also announced a dividend hike.